CDKL3 is a promising biomarker for diagnosis and prognosis prediction in patients with hepatocellular carcinoma
Experimental Biology and Medicine · 2024
DOI: 10.3389/ebm.2024.10106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Biology and Medicine, 2024. Verfasst von Qingsi Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Transfusion, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cyclin-dependent kinase-like 3 (CDKL3) has been identified as an oncogene in certain types of tumors. Nonetheless, its function in hepatocellular carcinoma (HCC) is poorly understood. In this study, we conducted a comprehensive analysis of CDKL3 based on data from the HCC cohort of The Cancer Genome Atlas (TCGA). Our analysis included gene expression, diagnosis, prognosis, functional enrichment, tumor microenvironment and metabolic characteristics, tumor burden, mRNA expression-based stemness, alternative splicing, and prediction of therapy response. Additionally, we performed a cell counting kit-8 assay, TdT-mediated dUTP nick-end Labeling staining, migration assay, wound healing assay, colony formation assay, and nude mouse experiments to confirm the functional relevance of CDKL3 in HCC. Our findings showed that CDKL3 was significantly upregulated in HCC patients compared to controls. Various bioinformatic analyses suggested that CDKL3 could serve as a potential marker for HCC diagnosis and prognosis. Furthermore, CDKL3 was found to be involved in various mechanisms linked to the development of HCC, including copy number variation, tumor burden, genomic heterogeneity, cancer stemness, and alternative splicing of CDKL3. Notably, CDKL3 was also closely correlated with tumor immune cell infiltration and the expression of immune checkpoint markers. Additionally, CDKL3 was shown to independently function as a risk predictor for overall survival in HCC patients by multivariate Cox regression analysis. Furthermore, the knockdown of CDKL3 significantly inhibited cell proliferation in vitro and in vivo , indicating its role as an oncogene in HCC. Taken together, our findings suggest that CDKL3 shows promise as a biomarker for the detection and treatment outcome prediction of HCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Blood Transfusion, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Anhui Provincial Key Laboratory of Microbiology and Parasitology, Hefei, Anhui, China.
- School of Public Health, Department of Hygiene Inspection and Quarantine, Anhui Medical University, Hefei, Anhui, China.
- Department of Gastroenterology, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China.
Zitieren
APA
Wu, Q., Lu, M., Ouyang, H., Zhou, T., Lei, J., Wang, P., & Wang, W. (2024). CDKL3 is a promising biomarker for diagnosis and prognosis prediction in patients with hepatocellular carcinoma. Experimental Biology and Medicine. https://doi.org/10.3389/ebm.2024.10106
Vancouver
Wu Q, Lu M, Ouyang H, Zhou T, Lei J, Wang P, et al. CDKL3 is a promising biomarker for diagnosis and prognosis prediction in patients with hepatocellular carcinoma. Experimental Biology and Medicine. 2024. doi:10.3389/ebm.2024.10106
BibTeX
@article{Wu2024,
author = {Wu, Qingsi and Lu, Mengran and Ouyang, Huijuan and Zhou, Tingting and Lei, Jingyuan and Wang, Panpan and Wang, Wei},
title = {CDKL3 is a promising biomarker for diagnosis and prognosis prediction in patients with hepatocellular carcinoma},
journal = {Experimental Biology and Medicine},
year = {2024},
doi = {10.3389/ebm.2024.10106}
}
EUVIMED